EA201591501A1 - Терапевтические средства на основе csf-1 - Google Patents

Терапевтические средства на основе csf-1

Info

Publication number
EA201591501A1
EA201591501A1 EA201591501A EA201591501A EA201591501A1 EA 201591501 A1 EA201591501 A1 EA 201591501A1 EA 201591501 A EA201591501 A EA 201591501A EA 201591501 A EA201591501 A EA 201591501A EA 201591501 A1 EA201591501 A1 EA 201591501A1
Authority
EA
Eurasian Patent Office
Prior art keywords
csf
liver
tools based
therapeutic tools
treatment
Prior art date
Application number
EA201591501A
Other languages
English (en)
Inventor
Стюарт Форбс
Дэвид Хьюм
Бэн Статчфилд
Дебора Гоу
Грэм Бэйнбридж
Теодор Олифант
Томас Л. Уилсон
Original Assignee
Юниверсити Корт Ов Де Юниверсити Ов Эдинбург
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201303537A external-priority patent/GB201303537D0/en
Priority claimed from GB201320894A external-priority patent/GB201320894D0/en
Application filed by Юниверсити Корт Ов Де Юниверсити Ов Эдинбург filed Critical Юниверсити Корт Ов Де Юниверсити Ов Эдинбург
Publication of EA201591501A1 publication Critical patent/EA201591501A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение предлагает композицию вещества, содержащую гибридный белок CSF-1 и способы ее использования при повышении регенерации или восстановлении функций повреждённой печени. Композиции вещества полезны при лечении заболеваний печени, например, при профилактике и/или лечении заболеваний печени и для улучшения результатов после хирургического вмешательства на печени.
EA201591501A 2013-02-28 2014-02-28 Терапевтические средства на основе csf-1 EA201591501A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201303537A GB201303537D0 (en) 2013-02-28 2013-02-28 CSF-1 based therapeutics
GB201320894A GB201320894D0 (en) 2013-11-27 2013-11-27 CSF-1 Therapeutics
PCT/GB2014/050595 WO2014132072A1 (en) 2013-02-28 2014-02-28 Csf1 therapeutics

Publications (1)

Publication Number Publication Date
EA201591501A1 true EA201591501A1 (ru) 2016-02-29

Family

ID=50336347

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591501A EA201591501A1 (ru) 2013-02-28 2014-02-28 Терапевтические средства на основе csf-1

Country Status (11)

Country Link
US (2) US20160040142A1 (ru)
EP (1) EP2961421A1 (ru)
JP (1) JP2016510977A (ru)
KR (1) KR20150121715A (ru)
CN (1) CN105142659A (ru)
AU (1) AU2014222509A1 (ru)
BR (1) BR112015020235A2 (ru)
CA (1) CA2901368A1 (ru)
EA (1) EA201591501A1 (ru)
MX (1) MX2015011199A (ru)
WO (1) WO2014132072A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017176804A1 (en) * 2016-04-04 2017-10-12 Massachusetts Institute Of Technology Compositions of crystallized hydrophobic compounds and methods of making and using same
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
BR112020007249B1 (pt) 2017-10-13 2022-11-22 Harpoon Therapeutics, Inc Roteína de ligação a antígeno de maturação de célula b, proteína de ligação multiespecífica e uso das referidas proteínas
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
GB201906975D0 (en) 2019-05-17 2019-07-03 Univ Edinburgh Treatment of ards
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
KR102384683B1 (ko) * 2020-05-07 2022-04-11 대한민국 구제역 바이러스 억제 활성을 갖는 신규한 돼지 인터페론-알파 융합 단백질 및 이의 용도
MX2023000197A (es) 2020-07-07 2023-02-22 BioNTech SE Arn terapeutico para el cancer positivo para vph.
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023246908A1 (zh) * 2022-06-21 2023-12-28 四川大学华西医院 靶向csf1r的嵌合抗原受体免疫细胞制备及其应用
CN115806626B (zh) * 2022-06-21 2024-02-23 四川大学华西医院 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
EP0702516A4 (en) 1993-06-01 1998-04-22 Life Technologies Inc GENETIC IMMUNIZATION WITH CATIONIC LIPIDS
AU2003235680A1 (en) * 2002-01-15 2003-07-30 Duke University Method of inhibiting atherosclerotic plaque destabilization
EP2311876A3 (en) * 2005-07-28 2011-04-27 Novartis AG M-CSF-specific monoclonal antibody and uses thereof
EP2089049A4 (en) * 2006-11-17 2011-11-16 Biogen Idec Inc SYSTEMIC ADMINISTRATION OF COLONIAL STIMULATING FACTORS TO TREAT AMYLOID ASSOCIATED DISEASES
SI2566517T1 (sl) * 2010-05-04 2019-01-31 Five Prime Therapeutics, Inc. Protitelesa, ki vežejo CSF1R

Also Published As

Publication number Publication date
US20180112193A1 (en) 2018-04-26
MX2015011199A (es) 2015-12-16
WO2014132072A1 (en) 2014-09-04
BR112015020235A2 (pt) 2017-10-10
US20160040142A1 (en) 2016-02-11
CN105142659A (zh) 2015-12-09
CA2901368A1 (en) 2014-09-04
KR20150121715A (ko) 2015-10-29
AU2014222509A1 (en) 2015-10-01
EP2961421A1 (en) 2016-01-06
JP2016510977A (ja) 2016-04-14

Similar Documents

Publication Publication Date Title
EA201591501A1 (ru) Терапевтические средства на основе csf-1
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790398A1 (ru) Способы лечения заболевания печени
EA201591908A1 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA202090683A3 (ru) Способы и композиции для лечения рака
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
PH12016502355A1 (en) Pharmaceutical composition
EA201690556A1 (ru) Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций
EA201590855A1 (ru) Соединения пирролопиримидина как ингибиторы киназ
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201591745A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA201591430A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201591426A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
MX2014011186A (es) Metodo para mejorar la eficiencia de las transfusiones de sangre.
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний